Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio director Ali Behbahani received a grant of stock options covering 14,677 shares of common stock at an exercise price of $10.59 per share. These options were awarded at no upfront cost and expire on June 9, 2036.
The options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, subject to his continued service as a non-employee director. Following this award, Behbahani holds 14,677 stock options directly.
Korro Bio, Inc. director Rachel Meyers received a grant of stock options as part of her compensation. The award covers 14,677 options to purchase Common Stock at an exercise price of $10.59 per share, all held directly after the transaction.
These options vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders, provided she continues serving as a non-employee director through that date. The options are scheduled to expire on June 9, 2036, giving a long-dated incentive aligned with the company’s share price performance.
Korro Bio, Inc. reported that director Nessan Bermingham received a stock option grant covering 14,677 shares of common stock. The option has an exercise price of $10.59 per share and expires on June 9, 2036. The option vests in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, subject to his continued service as a non-employee director.
Korro Bio director Katharine Knobil received a grant of stock options covering 14,677 shares of common stock at an exercise price of $10.59 per share. These options vest in full on the earlier of one year from the grant date or the next annual stockholder meeting, subject to her continued service as a non-employee director, and will expire on June 9, 2036.
Korro Bio director Jean Francois Formela received a stock option grant as equity compensation. The award covers 14,677 shares of common stock at an exercise price of $10.59 per share and expires on June 9, 2036. The option vests in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided he continues serving as a non-employee director through that vesting date.
Korro Bio director Timothy R. Pearson reported receiving a grant of stock options under the company’s equity plan. The award covers 14,677 options for Common Stock at an exercise price of $10.59 per share, with no cash paid for the grant itself.
The options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided he continues serving as a non-employee director through that date. Following this grant, Pearson holds 14,677 stock options directly, which expire on June 9, 2036.
Korro Bio, Inc. reported the results of its 2026 annual stockholder meeting held on June 10, 2026. Stockholders elected Nessan Bermingham and Rachel Meyers as Class I directors for three-year terms ending at the 2029 annual meeting.
Both directors received several million votes in favor, with additional votes withheld and broker non-votes recorded. Stockholders also approved, in a non-binding advisory vote, the compensation of Korro’s named executive officers by a wide margin.
In addition, stockholders ratified the selection of Ernst & Young LLP as Korro’s independent registered public accounting firm for the fiscal year ending December 31, 2026. These items collectively confirm continued support for the company’s board, executive pay program, and auditor.
Korro Bio, Inc. director and President & CEO Ram Aiyar reported a disposition of common stock primarily tied to equity compensation. On the reported date, 15,152 shares of common stock were sold at a weighted-average price of $12.98 per share solely to satisfy tax withholding obligations arising from the vesting and settlement of a performance stock unit award. Following this tax-related sale, Aiyar directly held 74,848 shares of common stock, and an additional 4,613 shares were held indirectly through The Ram Aiyar Irrevocable Trust, for which he serves as trustee and disclaims beneficial ownership except for any pecuniary interest. The filing also notes that his holdings include 40,000 shares of common stock issuable upon settlement of a restricted stock unit granted under the company’s 2023 equity plan.